FGFR2 and ovarian adenocarcinoma: FGFR2 fusions are common in a subset of cholangiocarcinoma and lung, breast, thyroid, and prostate adenocarcinoma (1–3) and rare in ovarian adenocarcinomas, while FGFR2 point mutations or gene amplification is more common (4, 5).